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The sequence of genomic alterations acquired by cancer cells during tumor progression and metastasis is poorly
understood. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that integrates cytoskeleton remodeling,
mitogenic signaling and cell survival. FAK has previously been reported to undergo nuclear localization during cell
migration, cell differentiation and apoptosis. However, the mechanism behind FAK nuclear accumulation and its
contribution to tumor progression has remained elusive. We report that amplification of FAK and the SUMO E3 ligase
PIAS1 gene loci frequently co-occur in non-small cell lung cancer (NSCLC) cells, and that both gene products are enriched
in a subset of primary NSCLCs.We demonstrate that endogenous FAK and PIAS1 proteins interact in the cytoplasm and
the cell nucleus of NSCLC cells. Ectopic expression of PIAS1 promotes proteolytic cleavage of the FAK C-terminus, focal
adhesion maturation and FAK nuclear localization. Silencing of PIAS1 deregulates focal adhesion turnover, increases
susceptibility to apoptosis in vitro and impairs tumor xenograft formation in vivo. Nuclear FAK in turn stimulates gene
transcription favoring DNA repair, cell metabolism and cytoskeleton regulation. Consistently, ablation of FAK by CRISPR/
Cas9 editing, results in basal DNAdamage, susceptibility to ionizing radiation and impaired oxidative phosphorylation.Our
findingsprovide insight into amechanismregulatingFAKcytoplasm-nuclear distribution anddemonstrate that FAKactivity
in the nucleus promotes NSCLC survival and progression by increasing cell-ECM interaction and DNA repair regulation.
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Protein inhibitor of activated STAT1 (PIAS1) is a SUMO E3 ligase
implicated in the regulation of several oncogenes and tumor suppressors
such as AKT, BRCA1, BRCA2, PML and PML-RARA [1–4]. In
addition, PIAS1 is over-expressed in prostate and lung cancers [4,5].
Moreover, increase in PIAS1 protein levels has recently been linked to
breast cancer tumorigenesis, albeit reports disagree as to the relevance of
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characterize the relevance of PIAS1 in non-small cell lung cancer
(NSCLC) progression and metastasis. We also investigated PIAS1
downstream targets that could account for the phenotype observed and
potentially serve as a therapeutic target in NSCLC.
Lung cancer metastasis is an indicator of poor prognosis and a main
determinant of cancer-related mortality. Consequently, targeting and
prevention of cancer cell metastasis is among the biggest hurdles in clinical
oncology [8]. During metastasis, cancer cells rely heavily on cell-
extracellular matrix (ECM) interactions, cytoskeleton remodeling and
gene transcription. An important player in these processes is focal adhesion
kinase (FAK). FAK is a non-receptor tyrosine kinase that contributes to
almost every aspect of metastasis; from ECM sensing, cytoskeleton
remodeling to gene transcription [9–12]. The FAK gene is rarely mutated
in human lung cancers, but theFAK locus (chromosome 8q) is frequently
amplified in lung, colon, breast and gastric tumors [13–16].
FAK controls cytoskeleton remodeling by transducing signals from
integrin receptors to ERK/MAPK, PI3K,RAC1 andRHOA [10,17–19].
Importantly, FAK promotes integrin β1 (ITGβ1) gene expression, which
in turn, increases the survival of cancer cells [20]. FAK has also been
linked to transcriptional activation of SNAIL, TWIST, ZEB1, and ZEB2
genes, which are essential for epithelial to mesenchymal (EMT)
reprogramming in epithelial cells [21–23]. However, whether FAK is
involved in transcriptional regulation is still a matter of debate because
FAK residesmainly in the cytoplasmwhere it is associatedwith the plasma
membrane. However, FAK protein can relocate to the cell nucleus during
cell differentiation or cancer progression [24,25]. Despite several studies
reporting FAK protein nuclear localization and involvement in gene
transcription, no unifying mechanism exists to explain the nuclear
accumulation of FAK and the potential implications of nuclear FAK for
tumorigenesis and metastasis.
Small ubiquitin-like modifiers (SUMO) have recently gained
attention because of their participation in the covalent modification
of target protein substrates, a process referred to as SUMOylation.
This process consists of an enzymatic cascade whereby SUMO
proteins are added onto target substrates with the involvement of E1,
E2 and a limited number of SUMO E3 ligases. Typically, only a
small fraction of a given protein is SUMOylated [26]. SUMOylation
has been implicated in several cellular processes that include the
regulation of nuclear import, DNA damage repair and signal
transduction, however its role in tumorigenesis is still incompletely
understood [27].
Using single nucleotide polymorphism (SNPs) data, we discovered
that PIAS1 and FAK are frequently co-amplified in lung cancer
specimens. We found a positive correlation between increased gene
copy number and FAK and PIAS1 protein levels in a subset of
NSCLC cell lines in vitro, human lung tumor samples in vivo and in a
mouse model of tumor metastasis. Herein, we report an interaction
between FAK-PIAS1 leads to FAK nuclear relocation, which is crucial
for the regulation of the turnover of focal adhesions, and cell survival
during oncogenic stress.
Materials and Methods
Gene Copy Number Analysis
SNP was performed as previously described [4]. Briefly, SNP
profile was obtained using Illumina DNA analysis Bead Chip
(Illumina, Inc.). PIAS1 and FAK gene copy number was extrapolated
from their relative probe intensity compared with diploid controls.Histochemistry and Immunofluorescence
Formalin-fixed, paraffin-embedded NSCLC specimens were
obtained from the human tumor tissue bank at UT Southwestern
Medical Center. Tissues and cells were processed for immunohisto-
chemistry (IHC) or immunofluorescence (IF) using standard
protocols [19]. See also supplementary methods.
Cell Lines and Tissue Culture
Human NSCLC cells and human bronchoalveolar epithelial cells
(HBECs) were from the Hamon Center Cell Line Repository and were
a gift of Dr. John Minna (UT Southwestern Medical Center) [28,29].
All cell lines were DNA-fingerprinted for provenance (PowerPlex 1.2
Kit; Promega) and Mycoplasma-free (e-Myco Kit; Boca Scientific).
NSCLC cells were cultured inRPMI supplementedwith 5% serum and
antibiotics. HBEC cells were grown in keratinocyte growth media with
supplements (Invitrogen, No.: 17005-042). NIH 3T3 were grown in
5% DMEM. All cells were maintained in humidified incubator with
5% CO2 at 37°C. See also supplementary methods.
Western Blotting and Immunoprecipitation
We followed standard protocols [19].
Soft Agar Colony Formation, Transwell Migration and
Scratch Assays
We performed these assays following established procedures [11,30].
Subcellular Fractionation
Cellular fractionation was carried out as previously described [31].
Cells were scrapedwith ice-cold PBS, pelleted by centrifugation at 600 g
for 5 minutes, suspended in hypotonic lysis buffer (10 mM Tris-base
pH 7.5, 10 mM KCl, 1.5 mM MgCl2) with protease/phosphatase
inhibitors for 10 minutes. Cells were then lysed by Dounce
homogenization and centrifuged at 3000×g to separate cytoplasmic
(supernatant) from nuclear (pellet) fractions. To extract nuclear
proteins, the nuclear pellet was resuspended in high salt buffer
(50 mM Tris-base, pH 7.9, 0.5 M NaCl) 2 mM EDTA, 10% sucrose,
10% glycerol) with protease and phosphatase inhibitors.
RNAi Interference
Stable lentiviral transduction was performed with pGIPZ Lentiviral
vectors containing shRNAs targetingPIAS1 and non-targeting scrambled
shRNA controls (Dharmacon). siRNA (siGenome) targeting PIAS1, or
non-targeting siRNA controls were purchased fromDharmacon. See also
supplementary methods.
Oxygen Consumption Rate Measurement
This assay was performed with a Seahorse XF analyzer following
the manufacturer's protocols (Seahorse Bioscience).
Mouse Xenografts
Xenografts were performed as described previously [32] and were
approved by the institutional IACUC guidelines.
Results
FAK and PIAS1 Genes are Frequently Co-Amplified in a
Subset of NSCLCs
Using SNPs gene copy number analysis we looked for novel
genomic cooperating alterations in a panel of 108 non-small cell lung
cancer (NSCLC) cells. This analysis revealed that approximately 8%
Figure 1. FAK and PIAS1 protein levels are correlated in NSCLC. (A) Heatmap shows single nucleotide polymorphism (SNPs) gene copy
number analysis for FAK and PIAS1 genes in the indicated lung cancer cell lines. Green, black and red indicate copy number loss, no
change or gene copy number gain, respectively. (B) Immunoblot confirms increment in FAK and PIAS1 at the protein level in a
representative panel of cells with gene amplification. Green, black and red horizontal lines indicate NSCLC cells with loss, no change or
gene copy number gain of PIAS1 and FAK. (C) Hematoxylin and eosin (H&E) and IHC stain of PIAS1, phospho-FAK (pFAK) and total FAK in
primary NSCLC samples. Insert shows cytoplasmic and nuclear positivity for both proteins (black arrowheads). Scale bar: 100 μm. (D) IHC
positivity score analysis of FAK and PIAS1 in human NSCLC tumor tissuemicroarrays samples (n = 330). Graph shows positive correlation
between increase positivity in FAK stain and PIAS1. Score =1 low intensity; 2 =moderate intensity; 3 = high intensity. Statistical analysis
was done using a Mann-Whitney U test. (E) H&E and IHC stain of PIAS1, phospho-FAK (pFAK) and total FAK in metastatic NSCLC. Insert
shows positivity for cytoplasmic and nuclear stain for both proteins. Scale bar: 200 μm. (F) Contingency table shows positive correlation
between FAK and PIAS1 IHC stain positivity in primary vs metastatic samples. The number of samples is indicated.
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PIAS1 genes (Figure 1A).
To investigate the relationship between gene copy number gain
and gene expression we detected FAK and PIAS1 by immunoblot in
cell lines representative of our larger panel of NSCLC cells. We found
that cell lines with increased PIAS1 gene copy number display
concordant increase in PIAS1 protein (Figure 1B). Since gene
amplification/deletions may result from adaptive responses to selective
pressures of tissue culture, we tested primary NSCLC specimens for
FAK and PIAS1 proteins using IHC. We found that primary NSCLC
samples exhibited elevated total FAK (tot-FAK), phospho-FAK (p-FAK;
Y397) and PIAS1 positivity compared to normal surrounding tissue
(Figure 1C, arrowhead). Using lung tumor tissue microarrays we further
confirmed that samples with high tot-FAK positivity score had a
concomitant increase in PIAS1 positivity, but not p-FAK positivity
(Figure 1D). Because FAK is associated with cell migration [9,33], we
tested paired primary and metastatic NSCLC samples for FAK and
PIAS1 protein levels. As observed in primary lung tumor samples, we
found a positive correlationwith FAK and PIAS1 protein levels in lymph
node metastasis, but not with p-FAK protein levels (Figure 1, E and F).
These observations suggest that PIAS1 and total-FAK protein levels
correlate with tumor progression, independent of FAK phosphorylation.
The KrasG12D/p53R172H mouse model (KP hereafter) faithfully
recapitulates aggressive human lung adenocarcinoma, developing
advanced lung tumors that are highly metastatic [34,35]. Metastatic
lung tumors in this mousemodel have been fully characterized and show
elevated expression of the ZEB1 transcription factor and activation of
Notch1 and Jagged2 signaling pathways, recapitulating the EMT
profiles associated with humanmetastatic NSCLC [36,37]. As in human
NSCLC, we found that KP lung tumors are positive for total-FAK and
PIAS1, but not for p-FAK (Supplementary Fig. 1A). Next we took
advantage of 393P and 344SQ lung cancer lines, which are a pair of lung
cancer cell lines derived from a KP lung specimen. 393P cells, were
derived from a primary lung tumor, are epithelial and have lowmetastatic
potential; while 344SQ cells were derived from a metastatic KP lung
tumor, are mesenchymal and are highly metastatic [34]. In this
experimental system we found that PIAS1 is significantly up-regulated
in vivo and metastatic cell line 344SQ (Supplementary Fig. 1B).
In view of these findings, we concluded that co-amplification of
FAK and PIAS1 genes occurs in a subset of primary human
NSCLC samples. Moreover, subsets of primary and metastatic
NSCLC samples have elevated PIAS1 and tot-FAK protein levels.
PIAS1 and FAK Proteins Physically Interact in NSCLC
We tested whether FAK and PIAS1 physically interact with co-IP
assays using NIH-3T3 cells transiently transfected with FAK or PIAS1
cDNAs. We successfully co-immunoprecipitated FAK with PIAS1 from
transfected NIH-3T3 cells (Figure 2A). Furthermore, we co-immuno-
precipitated endogenous FAK and PIAS1 proteins in several NSCLC
cells, which co-amplify FAK and PIAS1 genes (Figure 2B).
To gain insights into the location and stimulus required for FAK and
PIAS1 interaction, we performed cellular co-fractionation of endoge-
nous proteins during serum starvation, apoptosis or mitogenic
stimulation. To our surprise, we discovered that FAK and PIAS1
mostly co-purified in the cytosolic fractions, when cells were treated
with protein kinase C inhibitor (PKCi: Calphostin-C, a proapoptotic
agent), or serum for 2-4 hours post starvation, but not after stimulation
with epithelial growth factor (EGF) (Figure 2C lanes 5, 7 and 10).Using
IF and confocal microscopy we found significant co-localization ofendogenous FAK and PIAS1 at the nuclear periphery of serum treated
cells (Figure 2D). We subsequently performed immunoblot and
confocal co-localization studies with well-characterized organelle
markers following serum stimulation. Although partial localization of
PIAS1 and FAK can be seen with the endoplasmic reticulum protein
Calnexin, the dominant sites of interaction contain the RAB11 and
LAMP1, endosome associated proteins. These findings suggest that
internalization of growth factor receptors complexes promote the
association of FAK and PIAS1 proteins in endosomes localized in the
cytoplasm and nuclear periphery (Supplementary Fig. 2A-C).
To begin testing the biological significance of the interaction between
FAK and PIAS1, we determined the effects of Flag-Pias1 and or SUMO
overexpression on FAK proteins. We found that overexpression of
Flag-Pias1 or SUMO-1 did not promote a significant change in
tot-FAK or p-FAK (Figure 2E). However, expression of Flag-Pias1 or
the combination of Flag-Pias1 and SUMO1 resulted in the appearance
of a lower molecular weight species of FAK (Figure 2E arrowheads).
FAK was previously reported to undergo proteolytic cleavage by
Calpain proteases on its C-terminus to allow disengagement from
focal adhesions [38]. To test whether PIAS1 contributes to FAK
C-terminal cleavage we used a mutant (FakV744G) that abolishes FAK
protein C-terminal cleavage. Indeed, we found that the FakV744G is
resistant to PIAS1-induced FAK C-terminal proteolysis (Figure 2F).
Thus, we concluded that mitogenic signaling promotes FAK and
PIAS1 physical interaction, which correlates with PIAS1-induced
FAK C-terminal cleavage. Importantly, this phenotype is rescued by
using a FAK mutant resistant to proteolytic cleavage.
PIAS1-FAK Interaction Regulates Focal Adhesion Dynamics
Endogenous PIAS1 is mostly nuclear, but can also be found
scattered in the cytoplasm of lung cancer cells in vivo and in vitro
(Figures 1C and 2D). We hypothesized that PIAS1-FAK interaction
may affect focal adhesion dynamics and how cells integrate
extracellular signaling. To test this hypothesis, we used RNAi to
determine how PIAS1 affects F-Actin stress fiber formation. We
found that PIAS1 silencing in lung cancer cells destabilizes F-Actin
fibers and reduces Vinculin (VCL) localization to focal adhesions
(Figure 3A). Then we tested if the opposite was true using HBECs,
which are immortalized, but not transformed, by transduction of
CDK4 and human Telomerase Reverse Transcriptase (hTERT) [29].
Indeed, we found that ectopic expression of PIAS1 (Flag-Pias1) in
HBECs increases VCL puncta at focal adhesions, while also
promoting the nuclear localization of GFP-FAK (GFP-Fak)
(Figure 3B). We further tested for changes in VCL puncta formation
in live cells using mCherry labeled VCL (mCherry-VCL). We
measured the formation, duration and turnover of mCherry-VCL
focal adhesion, as inverse correlation to FAK-dependent turnover of
focal adhesions [11,38]. Compared to control shRNA, PIAS1
silencing increased the turnover of mCherry-VCL puncta; along the
leading and lagging edge of cells (Figure 3, C–F). Furthermore, we
found that Flag-Pias1 gene expression induces membrane ruffle
formation in fibroblasts and rescues endogenous VCL puncta loss in
GFP-Fak overexpressing cells (Supplementary Fig. 3A, B). Finally,
induction of membrane ruffles by PIAS1 correlates with increases in
Rac1-GTPase and ROCK-1 protein levels without an increase in
pFAK levels (Supplementary Fig. 3C).
In view of these findings we concluded that PIAS1 regulates focal
adhesion dynamics by promoting FAK nuclear localization and
directional cell motility.
Figure 2. PIAS1 and FAK physically interact in human NSCLC cell lines. (A) NIH 3T3 cells were transiently transfected with the indicated
plasmids and FAK and PIAS1 protein interaction was analyzed by co-IP followed by immunoblotting. (B) Immunoblot showing
endogenous PIAS1 and FAK protein co-IP in the indicated NSCLC cell lines. (C) Subcellular fractionation and immunoblotting of
endogenous FAK and PIAS1 proteins was performed in serum starved lung cancer cells H460 following treatment with: DMSO; EGF;
protein kinase C inhibitor Calphostin (PKCi) and 10% FBS. Fractions: C; cytosolic; M; matrix; N: nuclear. Note significant cytoplasmic FAK
and PIAS1 protein accumulation in PKCi and serum treatment, but not with EGF. (D) IF and confocal micrograph of FAK (red) and PIAS1
(green) localization at nuclear periphery in H460 NSCLC cells. Scale bar: 10um. (E) Immunoblot following Flag-Pias1 and Fak
overexpression in NIH-3T3. Blot shows no change in total FAK or pFAK (Y397), but note the appearance of low and higher molecular
weight species of FAK protein in cells overexpressing Flag-Pias1 or Flag-Pias1-SUMO1 overexpression, which correspond to
SUMOylated-FAK and cleaved FAK. (F) Cells were transfected withmCherry-Fakwt or mCherry-FAKV744G, a cleavage resistant mutation, in
combination with Flag-Pias1 and analyzed with immunoblot as indicated. Note that Flag-Pias1 promotes the cleavage ofmCherry-Fakwt as
expected, but cleavage of C-terminus mutant FAKV744G is impaired.
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Colonies on Soft Agar
To elucidate how PIAS1-FAK interaction can modulate lung
cancer progression we tested the effect of PIAS1 inhibition on cell
proliferation and survival. We found that PIAS1 silencing with a
short hairpin RNA (shRNA) had a modest effect on cell growth on
plastic for most NSCLC cell lines (Figure 4A). Next, we examined
how PIAS1 inhibition would affect growth of NSCLC cells in soft
agar. Indeed, following PIAS1 inhibition, we observed a marked
reduction in colony formation in soft agar assays (Figure 4, B–D).Next we tested whether PIAS1 inhibition may result in defective
p-FAK activation, which could explain the inability of NSCLC cells
with silenced PIAS1 to establish colonies in soft agar assays.
Surprisingly, p-FAK levels did not correlate with soft agar growth
impairment in lung cancer cells (Figure 4E). Notably, the degree of
knockdown achieved by shRNA A and B correlates with their effect
on cell viability (Figure 4A). However, PIAS1 silencing promotes
increase baseline levels of pro-apoptotic protein BIM in several lung
cancer cells including: H2228 and H1395 (Figure 4F). This finding
suggests that PIAS1 silencing does not directly affect p-FAK or
Figure 3. PIAS1 silencing reduces stable stress fiber formation. (A) IF image of filamentous Actin (F-Actin) fiber formation in H460 NSCLC
cells. White arrows indicate F-Actin fibers in control siRNA treated cells (Ctrl siRNA) or following PIAS1 gene silencing; yellow arrows
indicates Vinculin (VCL) protein localization to F-Actin fibers, which is lost in cells with PIAS1 silencing. Scale bar: 10 μm. (B) IF image of
VCL and GFP-FAK co-localization at F-Actin fibers in HBECs cells following ectopic Flag-Pias1 expression. Top row shows HBECs cells
expressing ectopic GFP-Fak and endogenous VCL. Bottom row image shows HBECs expressing ectopically expressed Flag-Pias1 and
GFP-FAK stained as indicated. Note FAK nuclear accumulation and increase in VCL puncta at focal adhesions (yellow arrows). Pink arrows
indicate co-localization of GFP-FAK and VCL proteins. Scale bar: 10 μm. (C) Confocal live cell imaging of H460 NSCLC cells examining
mCherry-VCL puncta formation dynamics in cells expressing the indicated shRNAs. Yellow arrows indicate sites of rapid focal adhesion
turnover over a time lapse of 25 minutes. (D-F) Histograms show the average time for mCherry-VCL puncta formation, duration and
turnover. Values represent an average of n = 3 cells.
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Figure 4. PIAS1 silencing impairs tumor progression in NSCLC cells with FAK gene amplification. (A) Histogram shows cell viability following
PIAS1 gene silencing. FAK gene copy number status is also indicated. (B) Representative soft agar colonies of NSCLC cells expressing the
indicated shRNA. Scale bar: 500 μm. (C) Quantification of soft agar colonies of H2228NSCLC cells 3 weeks post plating. (D) Quantification of
soft agar colonies of H460 NSCLC cells 10 days post plating. (E) H2228, H522, H460 and H1395 NSCLC cells were treated with the indicated
shRNAs and analyzed by Immunoblot with the indicated antibodies. (F) Immunoblot following PIAS1 shRNA knockdown in H2228, H460 and
H1395 NSCLC cells shows BIM pro-apoptotic protein upregulation. (G) Representative image of a Transwell migration assay performedwith
H460 cells expressing the indicated shRNAs. (H) Histogram shows the absolute number of migrating cells in triplicate wells following PIAS1
knockdown in lung cancer cell line H460. Student's t test = ***P b .001. (I) Representative image of a Transwell migration assay performed
with H1395 cells expressing the indicated shRNAs. (J) Histogram shows the absolute number of migrating cells in triplicate wells following
PIAS1 knockdown in H1395 cells. Student's t test = **P b .01.
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subcellular localization that are independent on FAK phosphoryla-
tion. Furthermore, these findings indicate that PIAS1 silencing lowers
the threshold for apoptosis in NSCLC cells.
Our analysis of human NSCLC samples suggested that PIAS1 and
FAK proteins are elevated in a subset of highly invasive tumors. Thus,
we tested whether PIAS1 silencing affects NSCLC cell invasion and
migration potential in vitro. To do this, we performed Transwell
migration and scratch assays in NSCLC cells with gene amplification of
FAK and PIAS1 [21,30,39]. In Transwell assays, H460 cells expressing
the control shRNA completed migration after 16 hours (16 h) [40],whereas cells expressing a shRNA targeting PIAS1 showed reduced
migration through Transwell membranes (Figure 4, G–H). These
findings were replicated in H1395 cells, another NSCLC cell line with
gene amplification of FAK and PIAS1 (Figure 4, I–J).
These results suggest that PIAS1 suppression significantly reduce
the migration capacity of NSCLC cells. Thus, we performed scratch
migration assays using NSCLC cells: H1792, H522 and H460 as
representative examples of NSCLC cells from our panel. We found
that PIAS1 suppression did not have an effect on H1972, which has a
loss of FAK gene copy number, but reduced the migration of H522
and H460, which have substantially higher levels of FAK and PIAS1
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the cytoskeleton following scratch formation in H460 cells by
staining for F-Actin and cells polarity with the GM130 Golgi maker.
After 8 hours, cells transfected with the siRNA control were oriented
towards the scratch site, whereas cells with PIAS1 silencing were not,
suggesting reduced ability to polarize towards the scratch site
(Supplementary Figure 4, G–H).
In view of our findings we conclude that PIAS1 suppression is
associated with reduced anchorage-independent growth. In addition,
PIAS1 silencing reduces cell polarization during stimulus-driven
migration in NSCLC cells with FAK and PIAS1 gene amplification.
PIAS1-FAK Interaction Regulates Gene Transcription
We determined that PIAS1 promotes focal adhesion maturation and
FAK protein nuclear accumulation. This phenotype was conserved in
NSCLC cells, NIH-3T3 fibroblasts and HBECs (Figure 5, A–B).
GFP-FAK nuclear accumulation also occurs in HBECs cells harboring
the oncogenic KRASG12D mutation and p53 knockdown, suggesting a
positive correlation with cancer progression (Figure 5B).
To test whether PIAS1-FAK interaction and FAK nuclear accumulation
are directly associated with a pro-tumorigenic gene transcription program,
we analyzed HBECs ectopically expressing GFP-Fak and Flag-Pias1. We
analyzed mRNA-transcript linearized data with the Benjamini-Hochberg
statistics (log ratio 0.6; and p value b 0.3) and subtracted values obtained
from HBECs expressing GFP-Fak alone or Flag-Pias1 alone to obtain
transcripts that change only when both genes are co-expressed in
HBECs. We identified 473 differentially up/down-regulated tran-
scripts, which we used for further characterization (GEO accession ID:
GSE73280). Using gene ontology analysis we uncovered that
co-expression of GFP-FAK and PIAS1 correlates with activation of
several transcriptional programs that include DNA damage repair genes,
oxidative phosphorylation genes and a pancreatic adenocarcinoma
signature (Figure 5D). This finding suggests that nuclear FAK may
participate in DNA repair and cell cycle progression, a hypothesis
consistent with the known function of PIAS1 in these processes [1,5].
To test whether FAK is involved in DNA repair or mitochondrial
metabolism, we targeted its deletion in NSCLC cells by CRISPR/Cas9
gene editing. First, we tested for changes in γH2AX and pCHK2,
which are well-knownDNA damage response genes [31,41].We found
that in addition to having baseline activation of γH2AX and
phospho-Chk2 (pCHK2), surrogate markers of DNA damage, FAK
null (FAK-) H460 NSCLC cells were hypersensitive to ionizing
radiation (IR) (Figure 5E). This result suggests a link between FAK
nuclear localization and DNA damage response in NSCLC cells. We
also tested the effect of FAK loss on oxidative phosphorylation by
assessing ATP production and oxygen consumption rate. We found
that in agreement with the perturbation in oxidative phosphorylation
signatures during PIAS1-FAK overexpression, FAK protein depletion
by CRISPR/Cas9 led to a reduced mitochondria ATP production and
oxygen consumption rates (Figure 5, F and G).
Taken together these results suggest that PIAS1, by promoting
FAK nuclear localization, promotes tumor progression by engaging
transcriptional programs that regulate DNA damage repair, and
oxidative phosphorylation.
PIAS1 Silencing is Detrimental for Xenograft Tumor Growth
In Vivo.
Lastly, we examined whether PIAS1 was required for tumor
engraftment in vivo by performing xenograft experiments.We comparedH460 cells growth rate in vivo following stable viral transduction of
control shRNA or a PIAS1 shRNA. Xenografts expressing PIAS1
shRNA showed a significant reduction in growth 15 days post
implantation as compared to controls (P b .05) (Figure 6A).
Furthermore, mice in the control group were euthanized on average
after 37-days due to tumor burden; whereas the survival of mice in the
PIAS1 shRNA group averaged 55 days (Figure 6B). We performed
postmortem histological analysis of xenograft tumors and found no
significant difference in cell morphology or vascularity (Figure 6C). We
then examined the contribution of shRNA harboring cells to the
xenograft using the GFP reporter in the shRNA vector backbone
and discovered a significant underrepresentation of GFP positive cells
in the PIAS1-shRNA treatment group as compared to shRNA controls
(**P b .05) (Figure 6, D–E).
In view of these findings, we concluded that PIAS1 is required for
the growth of tumor xenografts in vivo. Furthermore, PIAS1
inhibition is selected against during tumor growth as demonstrated
by the underrepresentation of PIAS1 shRNA expressing cells at the
experiment endpoint.
Discussion
Metastasis accounts for more than 90% of cancer related deaths
worldwide [34,35,42,43]. Consequently, identification of novel
biomarkers and potential therapeutic targets is of paramount
importance. FAK nuclear localization has been reported to be
important for disease progression in various cancer types and a
requirement during embryogenesis and tissue homeostasis
[40,44,45]. However, the mechanism that mediates FAK relocation
to the cell nucleus and if and how this enhances cell survival,
metastasis and tissue development has remained unclear [25,46].
Using SNPs data, we discovered that the SUMO-E3 ligase PIAS1
and FAK genes are co-amplified in a subset of NSCLC specimens.
Furthermore, we show a positive correlation between gene copy
number gain and increase in total FAK and PIAS1 protein levels,
using NSCLC cell lines in vitro and human lung tumor samples
in vivo. Interestingly, we found that FAK and PIAS1 protein are
elevated in a subset of primary and invasive human lung tissues and in
a bona fide mouse model of NSCLC metastasis [35].
It was previously reported that FAK and PIAS1 protein interact in a
yeast two-hybrid screen and in transfected HEK-293T cells. In this
setting PIAS1 promotes FAK phosphorylation at tyrosine 397 (Y397), a
key event for FAK activation [47]. We confirmed that endogenous
PIAS1 and FAK interact inNSCLC cells and this interaction is observed
at the nuclear periphery or within the cell nucleus. However, our
findings indicate that PIAS1 expression does not affect P-FAK or total
FAK protein levels in NSCLC, instead our data support the conclusion
that PIAS1 promotes changes in FAK subcellular localization that are
independent on its phosphorylation. Indeed, PIAS1 expression, or the
combined expression of PIAS1 and SUMO-1, results in the appearance
of a ~87 KDa form of FAK, previously reported as a Calpain-mediated
FAK cleavage product [38]. Indeed we found that using a point mutant
form of FAK protein (FakV744G), that renders FAK resistant to Calpain
proteolysis, the ~87KDa form of FAK was significantly reduced.
Because FAK cleavage is part of its negative regulation at focal
adhesions, we conclude that PIAS1may be involved in the regulation of
FAK and focal adhesion dynamics.
Recently, inhibition of PIAS1 was found to reduce breast cancer
tumorigenesis by increasing genomic instability and loss of stem cell
potential [7]. Silencing of PIAS1 in a subset of NSCLC cells with FAK
Figure 5. PIAS1 promotes FAK protein nuclear localization and gene transcription. (A) Immunoblot of immortalized HBECs transduced/
transfected with the indicated plasmids. Arrow indicates cleaved FAK. (B) Confocal microscopy of HBECs transduced as indicated. Note
the nuclear relocation of GFP-FAK after either ectopic Flag-Pias1 overexpression in HBECs or cells harboring KRASG12D mutations (green
and red arrows indicate cytoplasmic and nuclear FAK, respectively). Scale bar: 20 μm. (C-D) Heatmap and gene ontology analysis of
HBECs expressing GFP-Fak alone or in combination with Flag-Pias1. (E) Immunoblot of FAK wild type (FAK+) or FAK deleted (FAK-) H460
NSCLC cells treated with IR and harvested at the indicated time points. Note upregulation of p-CHK2 and g-H2AX in null cells, indicating
DNA damage hypersensitivity following FAK loss. (F) Histogram shows the change in ATP productions (pmol/min) and oxygen
consumption rate (OCR) in H460 NSCLC following FAK gene deletion. Analysis of mitochondrial function shows reduced ATP production
and oxygen consumption in FAK- H460 cells.
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focal adhesion turnover. We found that PIAS1 expression can promote
GFP-FAK nuclear accumulation and rescues the accumulation of VCL
puncta at focal adhesions. The latter correlates with an increase in the
activation of integrin downstream targets (RAC-1 and ROCK-1), but
not pFAK activation, as it is no longer at the cell membrane where its
phosphorylation is known to occur [48,49].
Although FAK is widely associated with metastasis [10,11,25], it is
still unclear whether PIAS1 or SUMOylation negates or contributesto tumor progression [5,50]. PIAS1 was reported to repress TGF-β
and reduced EMT transition in breast cancer cells by repression of
N-cadherin [6]. However, other reports suggest that PIAS1 is
necessary for breast cancer progression via activation of WNT5A,
regulation of the estrogen receptor (ER) signaling and promoting
tumor growth in vivo [7]. In our study, we found that PIAS1
silencing in NSCLC did not have an effect on EMT genes including
N-Cadherin or E-Cadherin (JDC and PPS, unpublished data).
However, PIAS1 silencing in NSCLC reduced cell polarization and
Figure 6. PIAS1 gene silencing impairs xenograft tumor growth in vivo. (A) The histogram shows the volume of xenografts from H460
cells grown subcutaneously in NOD-SCID mice following transduction with scrambled shRNA (shScr; black line) or PIAS1 shRNA
(shPIAS1; red line). Mice per group N = 7. (B) Kaplan–Meier curve of mice carrying xenografts shown in panel A. Mice were sacrificed
when the tumors reached 2000 mm3. (C) H&E histological analysis of xenografts expressing shScr or PIAS1 shRNA at the end point of the
experiment. Squares indicate the sections analyzed for the GFP reporter in the shRNA construct. (D) Anti-GFP IF shows loss of GFP
positive cells in the PIAS1 shRNA xenograft group compared to the scramble shRNA group. (E) Quantification of GFP positive cells in the
indicated xenograft sections. Student's t test = **P b .01.
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driven migration. Specifically, we observed deficient lamellipodia
formation and GM130 leading edge orientation following migration
stimulus in vitro, which may have contributed to cells inability to
integrate extracellular signaling and properly migrate. We proposethat FAK recruitment to the nucleus by means of increase interaction
with PIAS1, allows for focal adhesion maturation and increase
integrin signaling, as demonstrated by the appearance of lamellipodia
projections in Flag-Pias1 expressing cells. In contrast, lamellipodia are
decreased or absent in migrating cells after PIAS1 knockdown. PIAS1
292 FAK and PIAS1 in Lung Cancer Tumorigenesis Constanzo et al. Neoplasia Vol. 18, No. 5, 2016gene silencing in NSCLC cells also reduced cell viability,
independently of P-FAK activation. Following PIAS1 gene silencing
we observed a concomitant increase in BIM protein levels. In
addition, we also observed a significant decrease in soft agar growth
following PIAS1 knockdown.
An unexpected result in our study was that PIAS1-induced FAK
nuclear recruitment promotes DNA repair transcription program.
Because FAK deletion led to DNA-damage hypersensitivity, shown
by γH2AX and pCHK2 activation, we speculate that the
co-amplification of FAK and PIAS1 promotes DNA damage repair,
providing a survival advantage to genomically unstable tumors. In
fact, FAK was found to be a negative regulator of p53 tumor
suppressor in immortalized fibroblasts, and FAK inhibition radio-
zensitizes head and neck carcinoma [46,51]. Work is already in
progress to characterize in better detail the involvement FAK in DNA
damage repair and possible applications for NSCLC radiotherapy.
Another unexpected finding was that silencing of FAK is associated
with decrease of oxygen consumption and ATP production, an
observation that underscores the importance of FAK in the
maintenance of FAK-dependent NSCLC cells. Work is currently in
progress to further characterize this phenotype.
In agreement with previous findings in breast cancer, PIAS1
silencing affects NSCLC cells growth in soft agar in vitro and tumor
xenograft growth in vivo. We speculate DNA damage regulation in
NSCLC may provide the prosurvival signaling required for tumor
progression in PIAS1/FAK overexpressing cancers. It will be of
interest to identify the transcriptional modulators interacting with
FAK while in the nucleus, as they represent potential tumor
biomarkers or therapeutic targets.
Finally, our results show that a subset of NSCLCs has co-amplification
of FAK and PIAS1 and that these proteins are enriched in metastatic
NSCLC. We conclude that PIAS1 is oncogenic and that, at least in part,
this activity depends on its ability to promote FAK nuclear accumulation,
integrin signaling activation and DNA damage repair. We conclude that
the FAK-PIAS1 signaling axis is a novel regulator of NSCLC progression,
integrating extracellular cues that regulate cell survival, migration and the
DNA damage response. We propose that FAK-PIAS1 status would serve
as a biomarker for the selection of patients undergoing personalized cancer
treatment protocols likely to respond to FAK inhibitors currently in
clinical trials.
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